This article first appeared on GuruFocus .
Release Date: August 06, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Glanbia PLC ( GLAPF ) delivered a strong first half with adjusted EPS up 30% in constant currency, driven by robust growth across all three operating segments.
-
The company upgraded its full-year adjusted EPS guidance to 17-20% constant currency growth, reflecting strong momentum and confidence in the business.
-
Performance Nutrition saw like-for-like revenue growth of 16.9%, led by the flagship Optimum Nutrition brand, which delivered 25.2% growth with strong volume and pricing.
-
The group-wide transformation program is ahead of plan, with annual savings target increased from $60 million to $70 million by 2027, driven by supply chain and digital initiatives.
-
Glanbia PLC ( GLAPF ) continues to return value to shareholders, raising the interim dividend by 10% and completing a 100 million share buyback program.
Negative Points
-
Performance Nutrition margins were broadly flat year-over-year due to record-high whey protein costs, which continue to create significant headwinds.
-
The company is seeing early signs of consumer price elasticity in specific channels and pack sizes following multiple rounds of price increases, and expects some volume softness in H2.
-
Health & Nutrition EBITDA margins declined 110 basis points due to increased raw material costs, which are expected to persist into the second half of the year.
-
Supply chain disruptions from the ongoing Middle East conflict are causing increased costs and higher inventory levels, particularly impacting the Health & Nutrition segment.
-
The company faces a tougher comparable in H2 2026 due to lapping distribution gains from the prior year, which will moderate revenue growth.
Q & A Highlights
Q: Given the strong demand despite higher pricing, has this cycle changed your view on the structural resilience and pricing power of the sports nutrition category? Also, if whey prices remain high, dairy nutrition benefits, but performance nutrition margins face pressureis whey still a net positive for group earnings? And how much of the earnings upgrade should be considered structural versus cyclical? A: Hugh Maguire (CEO) stated that the category is experiencing a general increase in health and wellness demand, with GLP-1 and the inversion of the food pyramid in the US acting as tailwinds. He noted that growth rates are strong and accelerating, with no indication of decline. The company's pricing power is evident as they implement a third round of price increases, though they are watching for elasticity. Mark Garvey (CFO) added that all three segments are performing strongly and stand on their own, with dairy nutrition benefiting from high protein markets. He expressed confidence in the medium-term algorithm outlined in November and noted that momentum seems good heading into next year, suggesting the upgrade is partly structural.
Q: Can you elaborate on where you are seeing elasticity following the Q2 price increases, and how much of Optimum Nutrition's growth is driven by category growth versus distribution gains or competitor supply issues? A: Hugh Maguire (CEO) explained that elasticity has been limited and concentrated in specific markets, channels, and SKUs, often where competitors haven't yet moved on pricing. He attributed the strong growth to a combination of very strong category growth in health and wellness, clear category leadership from Optimum Nutrition, effective marketing, and a pragmatic approach to pricing strategy with thoughtful opening price points. He noted that the brand benefits from being the most reviewed and recommended in a digital world. Regarding competitors, he stated they are competing against major players and don't see supply as an issue for them, though smaller suppliers may face challenges.
Q: Is it correct to assume a double-digit price increase in Q3, and are you planning further pricing in late 2026 or early 2027? How are you assessing the magnitude relative to elasticity, and what are your expectations for marketing spend this year? A: Hugh Maguire (CEO) confirmed that price increases were implemented in Q2 and are hitting shelves in late August/early September, with further increases planned for Q3 and the back end of the year into 2027, subject to review based on raw material costs, elasticity, and demand. He noted that all competitors are moving on price, and any elasticity seen is often due to a lag in competitor moves. On marketing, he stated there is no pullback in spend; it remains substantial but is more focused on consumer recruitment and brand awareness, particularly internationally. Mark Garvey (CFO) added that margin progression is expected in the second half as pricing flows through, offsetting cost increases and transformation savings.
Q: How do you see reformulation to other protein sources playing out across your portfolio, and can you provide color on the decline in the healthy lifestyle brands and RTD/RTM performance? Is the 50 basis point margin expansion target for performance nutrition still the ambition? A: Hugh Maguire (CEO) clarified that reformulation is primarily about new innovation and giving consumers choice, not changing the core Gold Standard whey formulation. They are launching products with clear protein, collagen, and milk protein to broaden their protein portfolio. Regarding healthy lifestyle brands, he noted that Isopure is performing well, but the decline is driven by lapping a strong prior year, a club channel delisting, and lost distribution for Think, which will be relaunched with a new high-protein bar proposition at the end of the year. Mark Garvey (CFO) stated that margin progression is still forecast for the year, though moderated due to strong volumes and higher whey costs, with stronger second-half margins expected as pricing actions take effect.
Q: Given the strong demand, why didn't you see better operating leverage in H1 performance nutrition margins, and what are your expectations for marketing spend? A: Mark Garvey (CFO) explained that the company is seeing operating leverage, but it is currently offsetting the significant whey cost increases. Transformation savings and pricing will more than offset these costs in the second half, leading to margin progression. He noted that once the whey cost dynamic stabilizes relative to pricing, there will be upside to margin progression. Hugh Maguire (CEO) added that marketing spend is not being pulled back; it remains substantial but is more effective and focused on recruitment and brand building.
Q: Do you expect to gain incremental distribution space within retailers given the strong category backdrop, and can you provide an update on the whey supply environment and your own investment? What does the M&A pipeline look like? A: Hugh Maguire (CEO) confirmed that they expect to see good distribution gains, particularly for Optimum Nutrition, as retailers recognize these categories as drivers of foot traffic and expand shelf space. On supply, he noted that the 10-15% incremental supply they previously mentioned has come on stream and been absorbed by demand, with more supply expected. Their own WPI capacity investment will be used internally for performance nutrition or protein solutions. On M&A, he stated the pipeline is very active, primarily focused on the health and nutrition segment.
Q: Can you elaborate on Isopure's growth in H1 and the performance of the rest of the brand portfolio? Also, what is driving raw material inflation in health and nutrition, and how will it evolve into 2027? A: Hugh Maguire (CEO) stated that Isopure delivered very good double-digit growth in food, drug, and mass channels in the US, with strong household penetration growth, though overall numbers were pulled back by lapping a club channel delisting. The rest of the portfolio is impacted by Think's lost distribution, which will be addressed with a relaunch. Mark Garvey (CFO) explained that health and nutrition cost increases are primarily due to the Middle East conflict causing petrochemical feedstock challenges in Asia, leading to higher costs. They expect these to persist in the second half but remain confident in the 17-19% margin range, and may pass on pricing next year if the conflict continues.
Q: The whey price cycle has historically been cyclical, but it feels different this time. Do you think this uptick will reshape the performance nutrition industry, and how has your marketing investment strategy changed? A: Hugh Maguire (CEO) noted a fundamental shift in the whey cycle driven by strong demand, with new supply being absorbed by demand rather than causing price declines. He stated they are not planning for a decline in protein pricing next year. On marketing, he explained that while spend
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
